ARCHIVES

Immunotherapy Demonstrates Disease Control in Phase II Study

This article is from The Cancer Letter archive.

Vol. 35 No. 9 | September 28, 2012

Download PDF Visit The Full Archive

Related Articles

SEER Expects To Lower Cancer Incidence Rates for Blacks by 3%

September 27, 2002

Phase III Regorafenib Trial Meets PFS Primary Endpoint

June 29, 2012

Pazdur: Registration Trials Run By Groups Need Same Rigor As Industry Trials

March 25, 2011

ASCO Hit On Two Sides; AACR Split Criticized

June 26, 1992

Switching to Tasigna After Gleevec Therapy Can Achieve Deeper Molecular Response

December 28, 2012

RAC Grumbles, Gives Healy Guidelines For Compassionate Use Of Gene Therapy

January 22, 1993